Head-To-Head Review: VBI Vaccines (VBIV) and Merck & Co., Inc. (MRK)

VBI Vaccines (NASDAQ:VBIV) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Volatility & Risk

VBI Vaccines has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.


This table compares VBI Vaccines and Merck & Co., Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -1,895.74% -68.48% -50.79%
Merck & Co., Inc. 14.71% 36.83% 13.72%

Analyst Ratings

This is a breakdown of recent ratings and price targets for VBI Vaccines and Merck & Co., Inc., as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 2 0 3.00
Merck & Co., Inc. 0 5 10 0 2.67

VBI Vaccines presently has a consensus target price of $10.50, indicating a potential upside of 397.63%. Merck & Co., Inc. has a consensus target price of $76.57, indicating a potential downside of 2.50%. Given VBI Vaccines’ stronger consensus rating and higher probable upside, equities research analysts plainly believe VBI Vaccines is more favorable than Merck & Co., Inc..

Valuation and Earnings

This table compares VBI Vaccines and Merck & Co., Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines $3.36 million 61.33 -$63.60 million ($0.97) -2.18
Merck & Co., Inc. $42.29 billion 5.01 $6.22 billion $4.34 18.09

Merck & Co., Inc. has higher revenue and earnings than VBI Vaccines. VBI Vaccines is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

52.9% of VBI Vaccines shares are owned by institutional investors. Comparatively, 73.4% of Merck & Co., Inc. shares are owned by institutional investors. 16.2% of VBI Vaccines shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


Merck & Co., Inc. pays an annual dividend of $2.20 per share and has a dividend yield of 2.8%. VBI Vaccines does not pay a dividend. Merck & Co., Inc. pays out 50.7% of its earnings in the form of a dividend. Merck & Co., Inc. has increased its dividend for 7 consecutive years.


Merck & Co., Inc. beats VBI Vaccines on 11 of the 17 factors compared between the two stocks.

VBI Vaccines Company Profile

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.

Merck & Co., Inc. Company Profile

Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.